Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously ‘undruggable’ oncogenic or hyperactive Ras.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Blocking SHP2 prevents the loading of GTP into the RAS, and it is aimed to provide anticancer activity in this way [68,69].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SHP2 is a protein tyrosine phosphatase that promotes RAS signaling through multiple mechanisms, including facilitation of SOS1-mediated nucleotide exchange and regulation of KRAS conformational dynamics through dephosphorylation of Tyr32 and Tyr64 [8,9].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“Src homology region 2 domain-containing phosphatase 2 (SHP2) is a receptor-free protein-tyrosine phosphatase and regulates proliferation by activating the RAS–MAPK–ERK signaling pathway.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression
Wei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Sawaya, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1983 · Cited by 221
RetractedRETRACTED ARTICLE: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion
Feng, H., Liu, K. W., Guo, P., Zhang, P., Cheng, T., McNiven, M. A., Johnson, G. R., Hu, B., & Cheng, S. (2011) · Oncogene · doi:10.1038/onc.2011.436 · Cited by 78
RetractedComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citationThe Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
The Ras superfamily at a glance
Wennerberg, K., Rossman, K. L., & Der, C. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01660 · Cited by 1,352
Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., & Weinberg, R. A. (1993) · Nature · doi:10.1038/363045a0 · Cited by 1,215
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Increasing complexity of Ras signaling
Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202174 · Cited by 1,079
Milburn, M. V., Tong, L., deVos, A. M., Brünger, A., Yamaizumi, Z., Nishimura, S., & Kim, S.-H. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,059
Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033
The Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580
An Unidentified Virus which causes the Rapid Production of Tumours in Mice
HARVEY, J. J. (1964) · Nature · doi:10.1038/2041104b0 · Cited by 555
Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
Guanosine Triphosphatase Activating Protein (GAP) Interacts with the p21 ras Effector Binding Domain
Adari, H., Lowy, D. R., Willumsen, B. M., Der, C. J., & McCormick, F. (1988) · Science · doi:10.1126/science.2833817 · Cited by 506
Gliomagenesis: genetic alterations and mouse models
Holland, E. C. (2001) · Nature Reviews Genetics · doi:10.1038/35052535 · Cited by 461
Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment
Zhang, S. Q., Yang, W., Kontaridis, M. I., Bivona, T. G., Wen, G., Araki, T., Luo, J., Thompson, J. A., Schraven, B. L., Philips, M. R., et al. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00050-4 · Cited by 447
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2004) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 427
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G.-S. (2007) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 371
The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
Dance, M., Montagner, A., Salles, J.-P., Yart, A., & Raynal, P. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.002 · Cited by 361
Proliferation of human malignant astrocytomas is dependent on Ras activation
Guha, A., Feldkamp, M. M., Lau, N., Boss, G., & Pawson, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201455 · Cited by 337
Morphologic Responses to a Murine Erythroblastosis Virus 2
(1967) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/39.2.311 · Cited by 306
Louis, D. N., Holland, E. C., & Cairncross, J. G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61750-6 · Cited by 298
Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
Ding, H., Roncari, L., Shannon, P. T., Wu, X., Lau, N. C., Karásková, J., Gutmann, D. H., Squire, J. A., Nagy, A., & Guha, A. (2001) · PubMed · Cited by 271
Aceto, N., Sausgruber, N., Brinkhaus, H., Gaidatzis, D., Martiny-Baron, G., Mazzarol, G., Confalonieri, S., Quarto, M., Hu, G., Balwierz, P. J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2645 · Cited by 261
Jiang, B.-H., Aoki, M., Zheng, J. Z., Li, J., & Vogt, P. K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2077 · Cited by 259
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
Aberrant function of the Ras signal transduction pathway in human breast cancer
Clark, G. J., & Der, C. J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00694753 · Cited by 213
A Novel Role for Gab1 and SHP2 in Epidermal Growth Factor-induced Ras Activation
Montagner, A., Yart, A., Dance, M., Perret, B., Salles, J.-P., & Raynal, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410012200 · Cited by 204
Zhang, X., He, Y., Liu, S., Yu, Z., Jiang, Z.-X., Yang, Z., Dong, Y., Nabinger, S. C., Wu, L., Gunawan, A. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901645u · Cited by 199
Self-citationHanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K., & Nishida, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312498200 · Cited by 174
Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
M. Scott, L., R. Lawrence, H., M. Sebti, S., J. Lawrence, N., & Wu, J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209027 · Cited by 156
Inhibition of Angiogenesis by a Mouse Sprouty Protein
Lee, S. H., Schloss, D. J., Jarvis, L., Krasnow, M. A., & Swain, J. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006922200 · Cited by 153
Charpantier, E., Wiesner, A., Huh, K.-H., Ogier, R., Hoda, J.-C., Allaman, G., Raggenbass, M., Feuerbach, D., Bertrand, D., & Fuhrer, C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3497-05.2005 · Cited by 152
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Schubbert, S., Lieuw, K., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., Clapp, D. W., & Shannon, K. M. (2005) · Blood · doi:10.1182/blood-2004-11-4207 · Cited by 148
Cunnick, J. M., Dorsey, J. F., Munoz-Antonia, T., Mei, L., & Wu, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.18.13842 · Cited by 137
Loh, M. L., Reynolds, M. G., Vattikuti, S., Gerbing, R. B., Alonzo, T. A., Carlson, E. J., Cheng, J. W., Lee, C. M., Lange, B. J., & Meshinchi, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403492 · Cited by 121
Miyamoto, D., Miyamoto, M., Takahashi, A., Yomogita, Y., Higashi, H., Kondo, S., & Hatakeyama, M. (2008) · Oncogene · doi:10.1038/sj.onc.1211019 · Cited by 108
Sha, F., Gencer, E. B., Georgeon, S., Koide, A., Yasui, N., Koide, S., & Hantschel, O. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303640110 · Cited by 104
Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation
Bunda, S., Heir, P., Srikumar, T., Cook, J. D., Burrell, K., Kano, Y., Lee, J. E., Zadeh, G., Raught, B., & Ohh, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406559111 · Cited by 100
Self-citationSubstrate Specificity of Protein Tyrosine Phosphatases 1B, RPTPα, SHP-1, and SHP-2
Ren, L., Chen, X., Luechapanichkul, R., Selner, N. G., Meyer, T. M., Wavreille, A.-S., Chan, R., Iorio, C., Zhou, X., Neel, B. G., et al. (2011) · Biochemistry · doi:10.1021/bi1014453 · Cited by 94
SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans
Liu, K.-W., Feng, H., Bachoo, R., Kazlauskas, A., Smith, E. M., Symes, K., Hamilton, R. L., Nagane, M., Nishikawa, R., Hu, B., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43690 · Cited by 92
Somatic PTPN11 mutations in childhood acute myeloid leukaemia
Tartaglia, M., Martinelli, S., Iavarone, I., Cazzaniga, G., Spinelli, M., Giarin, E., Petrangeli, V., Carta, C., Masetti, R., Aricò, M., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05457.x · Cited by 78
Further Evidence for a Somatic KRAS Mutation in a Pilocytic Astrocytoma
Janzarik, W., Kratz, C., Loges, N., Olbrich, H., Klein, C., Schäfer, T., Scheurlen, W., Roggendorf, W., Weiller, C., Niemeyer, C., et al. (2007) · Neuropediatrics · doi:10.1055/s-2007-984451 · Cited by 71
Huang, H., Woo, A. J., Waldon, Z., Schindler, Y., Moran, T. B., Zhu, H. H., Feng, G.-S., Steen, H., & Cantor, A. B. (2012) · Genes & Development · doi:10.1101/gad.192054.112 · Cited by 70
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia
Yamamoto, T., Isomura, M., Xu, Y., Liang, J. B., Yagasaki, H., Kamachi, Y., Kudo, K., Kiyoi, H., Naoe, T., & Kojma, S. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.02.004 · Cited by 70
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Huang, W.-Q., Lin, Q., Zhuang, X., Cai, L.-L., Ruan, R.-S., Lu, Z.-X., & Tzeng, C.-M. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140717105001 · Cited by 69
Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors
Martinelli, S., Carta, C., Flex, E., Binni, F., Cordisco, E. L., Moretti, S., Puxeddu, E., Tonacchera, M., Pinchera, A., McDowell, H. P., et al. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.10.003 · Cited by 57
Scott, L. M., Chen, L., Daniel, K. G., Brooks, W. H., Guida, W. C., Lawrence, H. R., Sebti, S. M., Lawrence, N. J., & Wu, J. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.117 · Cited by 48
Zhan, Y., Counelis, G. J., & O'Rourke, D. M. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.05.001 · Cited by 47
Mattingly, R. R. (2013) · ISRN Oncology · doi:10.1155/2013/536529 · Cited by 43
Chung, C. D., Jalali, S., Foltz, W. D., Burrell, K. E., Wildgoose, P., Lindsay, P. E., Graves, C. A., Camphausen, K. A., Milosevic, M., Jaffray, D. A., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.07.005 · Cited by 33
Self-citationNoonan Syndrome and Neuroblastoma
Cotton, J. L. (1995) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1995.02170240098019 · Cited by 28
Noonan syndrome associated with neuroblastoma: a case report
Lopez-Miranda, B., Westra, S. J., Boechat, M. I., & Yazdani, S. (1997) · Pediatric Radiology · doi:10.1007/s002470050140 · Cited by 27
Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma
Sturla, L.-M., Zinn, P. O., Ng, K., Nitta, M., Kozono, D., Chen, C. C., & Kasper, E. M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.345 · Cited by 27
Sprouty: a controversial role in receptor tyrosine kinase signalling pathways
Li, X., Wheldon, L. M., & Heath, J. K. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311445 · Cited by 24
Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation
Rankin, J., Short, J. P., Turnpenny, P. D., Castle, B., & Hanemann, C. O. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36005 · Cited by 17
Research works printed but not linked: 1
- Kirsten, W. H. & Mayer, L. A. Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311–335 (1967).
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“While the direct pharmacological inhibition of RAS is still being explored, alternative approaches to targeting RAS regulators such as PHLPP, SHP-2, and NF-2 have also been proposed [162,169,170].”
BackgroundKRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Edouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 237
Metadata
- Authors
- Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Princess Margaret Cancer Centre (CA)
- Indiana University Indianapolis (US)
- Corresponding author
- Ohh, Michael
- Venue
- Nature Communications
- Published
- 2015-11-30
- Volume
- 6
- Issue
- 1
- Pages
- 8859-8859
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4674766
- OpenAlex
- W2254051095
- Cited by
- 249
- References
- 63
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 29 · 2023: 36 · 2022: 30 · 2021: 30 · 2020: 17 · 2019: 20 · 2018: 15 · 2017: 21 · 2016: 10
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- PMC
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA69202, R01CA069202)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- SHP2, protein tyrosine phosphatase, Raf activation, glioblastoma, astrocytes, oncogenic Ras, therapeutic target, cell proliferation, tumor growth
- MeSH terms
- Animals, Cell Line, Female, Glioblastoma, Humans, Male, Mice, Inbred ICR, Phosphorylation, Oncogene Protein p21(ras), Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.